CSF2 and pulmonary alveolar proteinosis: This exploratory study was undertaken to determine levels and ranges of biomarkers potentially associated with aPAP, which could be used alone or in combination to monitor for pulmonary alveolar proteinosis onset in healthy human subjects or in patients with underlying respiratory diseases receiving anti-GM-CSF antibodies therapeutically.